Ebola virus: current and future perspectives

Infect Disord Drug Targets. 2015;15(1):20-31. doi: 10.2174/1871526515666150320162259.

Abstract

The present outbreak associated with Ebola disease in Western countries of the African continent which is believed to be one of the massive eruptions caused by the Ebola viral infections. In the present scenario ebola has been transmitted to the European and American regions through the travelers from wide spread countries like Guinea, Liberia, Sierra Leone and Nigeria. The viral disease is spreading through the contact in any form by the infected persons or patients and creating huge risks to the mortals. The symptoms related to ebola virus are often highly pathogenic; about 70-80% of death cases are reported due to critical hemorrhagic fever. Early in infection, ebola virus infects macrophages and endothelial cells. It mainly produces a Viral Protein 24 (eVP24) which prevents interferon-based signals which are important for destruction of viruses. How ebola virus manipulates the function of the immune system is still unclear. Due to lack of this knowledge, no approved treatment is available. In this review, we have tried to compile the epidemiology, pathogenesis and treatment of ebola virus infection. The promising ligands against ebola virus have been also discussed which will be helpful for researchers to design drugs for the treatment of ebola virus disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Africa / epidemiology
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Ebola Vaccines
  • Ebolavirus* / drug effects
  • Ebolavirus* / genetics
  • Ebolavirus* / immunology
  • Ebolavirus* / pathogenicity
  • Epidemics
  • Hemorrhagic Fever, Ebola / epidemiology*
  • Hemorrhagic Fever, Ebola / immunology
  • Hemorrhagic Fever, Ebola / therapy*
  • Hemorrhagic Fever, Ebola / virology
  • Humans
  • Liberia / epidemiology

Substances

  • Antiviral Agents
  • Ebola Vaccines